Roles
- Senior and Associate Editor Board
1. Financial interests
Yes
Please specify
I have received consultancy fees from WHO for conduct of systematic reviews relating to treatment of tuberculosis
Since 2020 I have been an academic partner in the UNITE4TB consortium, a new public-private partnership funded by the European Union Innovative Medicines Initiative and the European Federation of Pharmaceutical Industries until 2028. However, though this role involves engagement with industrial partners (GSK, Janssen, Evotech) in pre-competitive areas of research into TB drug development, these activities are fully supported by public funding from the EU and neither myself nor my research institution receive any funding from EFPIA or from the individual industrial partners.
From June 2019-June 2023 I was a co-investigator on a grant from ViiV Healthcare focusing on drug interactions between higher dose rifampicin and dolutegravir. However, I received no personal, salary or other financial benefits from this grant.
I have attended expert advisory meetings relating to TB drug development convened by GSK and Janssen for which I received no payment or benefit (honorarium, expenses, hospitality)
2. Non-financial interests
No
3. Do you hold any financial or non-financial ties with the Cochrane Collaboration, past or present
No
4. Commercial organisation with an interest in any topic related to health care or medical research
No
